Cancer Driver Interception™

Cancer doesn't happen overnight.

Before there is cancer to detect, there is biology to follow. Helixafe is a longitudinal blood-testing program that follows cancer-related molecular changes over time to assess your Cancer Driver Condition™, with the Bioscience Institute medical team telling you what those changes mean and what can be acted on.

Join the US waitlist

Helixafe is opening in the United States. Leave your email and we will write to you when enrollment opens.

Cover of the Helixafe guide to Cancer Driver Interception

Join the waitlist and we'll send you our guide to Cancer Driver Interception, twenty-six pages on what comes before cancer.

By joining you agree to receive email from Helixafe about the US launch. Unsubscribe any time.

  • Reviewed by Bioscience Institute physicians
  • Blood-based
  • Longitudinal
The window for Interception

We're not earlier. We're before.

Cancer doesn't develop in a single moment. Before there is cancer to detect, cancer drivers can emerge. Protective systems can weaken. What matters is how those changes behave over time.

Risk

What risk did I inherit? Hereditary cancer testing looks at genetic variants inherited from your parents.

This is where we operate

Interception

What is changing now? Helixafe follows selected acquired molecular changes over time, in the window between knowing your risk and detecting cancer.

This is where we operate.

Detection

Is there cancer to find? Screening and detection look for cancer, precancerous abnormalities, or evidence of disease.

Three different questions. Three different jobs. Helixafe operates before cancer. We call it Cancer Driver Interception™.
What we assess

What is a Cancer Driver Condition™?

Before cancer, changes can emerge in genes involved in controlling cell growth, repairing DNA, and protecting genomic stability. One change at one moment doesn't tell the whole story. What matters is what happens over time.

A Cancer Driver Condition™ is an evolving pattern of cancer-related molecular changes, identified by following selected acquired changes across repeated Helixafe tests.It is not cancer. It does not mean you have cancer. It is something our physicians follow with you.

What is a Cancer Driver Condition™?
Why are you looking before?

Wherever you're starting from, there's a way in.

I have hereditary cancer risk

You know the risk you inherited. What is happening now? Cancer Driver Interception follows what is changing in your biology today.

I've been through cancer

Your treatment ended. Your follow-up didn't. What happens between checks?

I'm already following a risk condition

The time between checks is no longer empty time. Add a longitudinal molecular view alongside the surveillance already recommended for you.

Cancer runs in my family

Your family history tells you why to pay attention. Cancer Driver Interception gives you another question to ask: what is changing now?

I want to be proactive

You already follow other areas of your health before disease. Now you can follow the biology before cancer.

Be first in line

Enrollment opens in the United States. The waitlist is how you will hear about it.

Our guide to Cancer Driver Interception, twenty-six pages on what comes before cancer, in your inbox.

Join the waitlist
The clinical framework

Interception is guided by our physicians.

Helixafe provides the longitudinal molecular information, and the Bioscience Institute medical team turns it into something you can act on. Our physicians review your baseline, interpret what changed, explain which findings are actionable, determine when to test again, and guide the appropriate next steps.

Helixafe follows the biology. Our physicians tell you what it means, and what can be acted on.

Interpreted by Bioscience Institute physicians Actionability guidance Longitudinal record

Cancer doesn't happen overnight.

Before cancer, there is biology to follow. Start following yours.

Join the US waitlist

Helixafe is opening in the United States. Leave your email and we will write to you when enrollment opens.

Our guide to Cancer Driver Interception, twenty-six pages on what comes before cancer, in your inbox.

By joining you agree to receive email from Helixafe about the US launch. Unsubscribe any time.